Posts for Ticker ‘ASTM’

GE Taking Decisive Step Into Stem Cells (GE, GERN, STEM, ASTM)

GE LogoGeneral Electric Company (NYSE: GE) is taking a bold and controversial new step into the field of embryonic stem cell research.  The company has signed an exclusive license and alliance pact with Geron Corporation (NASDAQ: GERN) to develop and commercialize cellular assay products derived from human embryonic stem cells for use in drug discovery, development and toxicity screening.  As noted over at BioHealthInvestor.com, this may have implications for other stem cell stocks such as StemCells Inc. (NASDAQ: STEM), Aastrom Biosciences, Inc. (NASDAQ: ASTM) and others.
Read More »

Posted on: June 30, 2009 – 9:17 am in Biotech, Conglomerates, Drug companies, Law, Medical, Politics, , , ,

Should You Chase Stem Cell Stocks? (ASTM, CYTX, GERN, NBS, OSIR, STEM, KOOL)

money-stack-image15We are seeing massive gap-ups this morning in stem cell stocks.  President Obama is signing an executive order which will lift the Bush ban on funding of embryonic stem cell funding.  What is interesting here is that this is not really new news other than the timing and the formality.  The following prices are as of 8:19 AM EST.

  • Aastrom Biosciences, Inc. (NASDAQ: ASTM) +87% at $0.62
  • Cytori Therapeutics, Inc. (NASDAQ: CYTX) +38% at $3.20
  • Geron Corporation (NASDAQ: GERN) +29% at $4.99
  • Neostem, Inc. (AMEX: NBS) NOT TRADED
  • Osiris Therapeutics, Inc. (NASDAQ: OSIR) NOT TRADED…. in pact with Genzyme, but for adult stem cells.
  • StemCells Inc. (NASDAQ: STEM) +55% at $2.15
  • Thermogenesis Corp. (NASDAQ: KOOL) +41% at $0.57

Many of these stem cell stocks will trade more on a “vote of confidence” rather than over what this means as far as “new news” is concerned.

JON C. OGG

Posted on: March 9, 2009 – 7:29 am in Biotech, Politics, , , , , , ,

Super Tuesday Election Winner: STEM CELLS (STEM, GERN, ASTM, IVGN, KOOL, NBS, OSIR)

Despite not knowing whom the ultimate winner of the 2008 Presidential election will be, it looks like stem cells may be one of the real bright spots as far as which area in biotech will be open for more funding down the road.  If the Democrats win this is a shoe in.  If McCain wins, the current research clamp-downs won’t likely be as stringent in 2009 and beyond as they are today.  If Romney stages a comeback, despite many thinking of him as a religious figure our indications are that he at worst would not be anywhere as tough on the stem cell studies as the current administration.  Public companies such as StemCells Inc. (NASDAQ: STEM), Geron Corporation (NASDAQ: GERN), Aastrom Biosciences, Inc. (NASDAQ: ASTM), and others are going to be watching closely.

If you look at Tradesports.com for the political futures, you can see the Presidential nominee futures right now if you want to make a determination where the actual money bets are going right now.  McCain is priced at $93.00 and Romney is now priced at $1.90, so this would indicate a 92.9% probability of a McCain nomination.  The Democrat race is much closer right now with Tradesports showing a Hillary Clinton nomination with a $54.60 price (down $8.40), and Obama with a $47.40 price (up $8.90).  So the futures are showing a McCain essentially as a shoe-in now, yet the Democrat race is still too close to call.  Guess what, this would be a win-win for stem cell research beyond this year.

Read More »

Posted on: February 6, 2008 – 9:33 am in Biotech, Politics, , , , , , , , , , , , , ,

Obama & Clinton Criticize Bush Stem Cell Veto (STEM, GERN, ASTM)

Stock Tickers: STEM, GERN, ASTM

Senator Obama has issued a statement regarding President Bush’s veto of the Embryonic Stem Cell Bill:

Senator Obama noted:  "By vetoing funding for stem cell research once again, the President is deferring the hopes of millions of Americans who do not have the time to keep waiting for the cure that may save or extend their lives. The promise that stem cells hold does not come from any particular ideology, it is the judgment of science, and we deserve a President who will put that judgment first and make this promise real for the American people."

Hillary Clinton noted (condensed): "You know, later today, apparently, the president will veto a bill passed by Congress to support stem cell research……Now, this is research that…holds such promise for devastating diseases. Yesterday, I met with a group of children suffering from juvenile diabetes. I co-chair the Alzheimer’s caucus in the Senate. I’ve worked on helping to boost funding for research to look for cures and a way to prevent so many devastating diseases. And we know that stem cell research holds the key to our understanding more about what we can do. So let me be very clear: When I am president, I will lift the ban on stem cell research…. This is just one example of how the President puts ideology before science, politics before the needs of our families, just one more example of how out of touch with reality he and his party have become. And it’s just one more example as to why we’re going to send them packing in January 2009, and return progressive leadership to the White House."

Stem cell investing is an issue that is frankly more politically igniting than perhaps any other issue for investors.  The key stem cell stocks that investors place bets on with the rise and fall of stem cell issues are StemCells Inc. (STEM-NASDAQ), Geron (GERN-NASDAQ), and Aastrom Biosciences (ASTM-NASDAQ).  It is always interesting which politicians and which candidates are pro or con on political issues that have implications for individual stock sectors.  If stem cell investing is yor primary focus, Obama is one of your friends. If not, well that answer is obvious too.

StemCells (STEM) closed down 2.3% at $2.48; Geron (GERN) closed down 3.1% at $7.39; and Aastrom (ASTM) closed down 2.1% at$1.39.

Jon C. Ogg
June 20, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in any of the companies he covers

Posted on: June 20, 2007 – 5:10 pm in Biotech, , ,